Click here for slides on this topic


Type 1 diabetes

Diabetes resulting from autoimmune destruction of pancreatic beta-cells. Type 1 diabetes typically occurs before age 30 but can occur at any age. Because of the beta-cell destruction, endogenous insulin is very low or absent. Patinets require endogenous insulin to survive and to regulate blood glucose levels.
The following content matched the glossary term: Type 1 diabetes

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

Top

Henry RR, Rosenstock, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2014; Epub ahead of print. DOI: 10.2337/dc13-2955.

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

ADA 2016 Children & Adolescents

Top

Recommendations for treating and managing diabetes in children from the 2016 ADA guidelines

ADA 2016 Type 1 Diabetes Pharmacologic Therapy

Top

Type 1 diabetes treatment options from the 2016 ADA guidelines

American Diabetes Association (ADA) Nutrition Guidelines for Adults With Diabetes

Top

Diabetes management guidelines for nutrition from the American Diabetes Association (ADA)

Clinical Insights in Diabetes Newsletter July 2013

Top

Clinical Insights® in Diabetes newsletter July 2013

Carotid intima-media thickness (CIMT) change in ORIGIN-GRACE, effects of omega-3 fatty acids on CV events in the Risk and Prevention Study, canagliflozin therapy in CANTATA-D2 and CANTATA-M, weight gain and intensive therapy in ACCORD, glycemic control with single daily basal insulin plus corrective glulisine and basal bolus regimen, diurnal pattern to insulin action in type 1 diabetes.

NDEI.org Expert Commentary on Diurnal Pattern to Insulin Action in Type 1 Diabetes Vivian Fonseca

Top

Expert commentary from NDEI Education Council Member Vivian A. Fonseca, MD, on data exploring whether a diurnal pattern to insulin action exists in type 1 diabetes

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Type 1 diabetes Slides Found: 888
Adjunctive Metformin Therapy in Insulin-Treated Patients With Type 2 Diabetes and Suboptimal Glycemic Control
DIGAMI: Cumulative Mortality After Acute MI in Type 2 Diabetes - Total Cohort
DIGAMI: Cumulative Mortality After Acute MI in Type 2 Diabetes: Low-Risk/No Previous Insulin
DPP: Incidence of Type 2 Diabetes
Ethnicity vs Race
Type 2 Diabetes in Youth A Growing Problem
Prevalence of the Insulin Resistance Syndrome (NCEP) in the US Population
Family History of Diabetes and Risk for Insulin Resistance in Mexican Amercians
Association Between Insulin Sensitivity and Physical Exercise The IRAS Study
Treating Insulin Resistance Reduces Incidence of Type 2 Diabetes
Treating Insulin Resistance Preserves b-Cell Function
Prevalence of Retinopathy in the San Luis Valley Diabetes Study
Microvascular Complications in Hispanics and Non-Hispanic Whites
Retinopathy Complications in Patients With Type 2 Diabetes
Nontraumatic Lower Extremity Amputation and Type 2 Diabetes
Nontraumatic Lower Extremity Amputation and Type 2 Diabetes (cont'd)
Hypertension and Glucose Tolerance in Four Ethnic Groups
Incidence of Type 2 Diabetes-Related Vascular Disease in Four Ethnic Groups
Results From a Culturally Sensitive Behavioral Management Program
Risk of Type 2 Diabetes in People With Impaired Glucose Tolerance
Type 2 Diabetes Prevention Studies
US DPP Incidence of Type 2 Diabetes With Different Interventions
Diabetes Incidence Rates by Ethnicity With Different Interventions
Assessing Risk: BMI and Waist Circumference
Assessing Risk for Morbidity and Mortality: Comorbidities and Other Risk Factors
Relationship Between Flow-Mediated Brachial Artery Dilation and Weight Loss After Lifestyle Modification
Changes in Flow-Mediated Brachial Artery Dilation After 6 Months of Lifestyle Modification
Effect of Diet and Exercise on Adipokines
Effect of Phentermine on Weight Loss in Obese Patients With Type 1 or Type 2 Diabetes
Effect of Sibutramine on Weight Loss in Obese Patients With Type 2 Diabetes Treated With Sulfonylurea
Effect of Sibutramine on Weight Loss in Obese Patients With Type 2 Diabetes Treated With Metformin
Effect of Orlistat on Weight Loss in Patients With Type 2 Diabetes
Effect of Orlistat on Weight Loss in Patients With Type 2 Diabetes
Effect of Orlistat on the Prevention of Type 2 Diabetes: XENDOS
Effect of Orlistat on Lipids and Glycemic Control in Patients
Effect of Sibutramine, Orlistat, and Metformin on Risk Factors for Type 2 Diabetes
Effect of Bariatric Surgery on Acute Insulin Response
Effect of Roux-en-Y Bypass on Treatment of Type 2 Diabetes
Cumulative Incidence of Diabetic Retinopathy and Proliferative Diabetic Retinopathy in Type 2 Diabetes by HbA1c Quartiles
Adjunctive Metformin Therapy in Insulin-Treated Patients With Type 2 Diabetes and Suboptimal Glycemic Control
DPP: Incidence of Type 2 Diabetes
Association of Stroke With Baseline Glycemic Factors in Patients With Type 2 Diabetes Followed for 3.5 Years
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Effect of Early Thiazolidinedione Therapy on A1C Levels
Effect of Early Thiazolidinedione Therapy on C-Peptide Levels
Effect of Early Thiazolidinedione Therapy on Diabetes Onset
Diabetes Is Undertreated Even When Atherosclerosis Present
IRAS: Number of CVD Risk Factors and Conversion to Type 2 Diabetes
Meta-Analysis: A1C and CVD in Type 2 Diabetes
Diabetes Is a Risk Factor for PAD and Its Associated Mortality
Gender Differences Influence Impact of Type 2 Diabetes on CHD Risk
ARIC: Association Between MetS Components and CHD Risk
CARDIA: Fast-Food Frequency and Insulin Resistance
Elective Coronary Revascularization in Patients With Type 2 Diabetes
Glycemic Control and Risk of Development of Heart Failure in Diabetes
Heart Failure Is More Common in Patients With Type 2 Diabetes
Pioglitazone Decreases Carotid IMT Independent of Glycemic Control in Patients With Type 2 Diabetes
Exenatide: Clinical Pharmacology
Exenatide: Effects on Glycemic Control in Combination With Current Oral Therapies
Exenatide: Proportion of Patients Achieving A1C <=7%
Pramlintide Adjunctive Therapy Offers Long-Term Glycemic Control
Effect of Pramlintide Adjunctive Therapy on Weight in Patients With Type 2 Diabetes
Adverse Events Associated With Thiazolidinedione Treatment
GLAI: Enrollment Criteria
ALLHAT: Clinical Outcomes in Antihypertensive Treatments
DIGAMI 2: Cumulative Mortality After Acute MI in Type 2 Diabetes
Pioglitazone Reduces VLDL-TG Levels by Increasing LPL-Mediated Lipolysis
PROactive: Objective/Endpoints
PROactive: Time to Primary Composite Endpoint
PROactive: Time to Main Secondary Composite Endpoint (Death, Nonfatal MI, or Stroke)
Waist Circumference, TG Levels Predict Future MetS in 18- to 19-Yr-Old Females
DCCT/EDIC: Incidence of Any Cardiovascular Disease Outcome
DCCT/EDIC: Incidence of Nonfatal MI, Stroke, or Death
Comparison of Diabetes Rates Across PIPOD and TRIPOD
Framingham Offspring Study: 8-Year Incidence of Type 2 Diabetes by BMI
Type 2 Diabetes in US Adults: Overview
GLP-1 Release Is Reduced in Type 2 Diabetes
GLP-1 Infusion Improves Beta-Cell Insulin Secretion
GLP-1 and First-Phase Insulin Secretion
Exenatide: Effect on the Beta-Cell
Vildagliptin Monotherapy Improves Glycemic Control in Type 2 Diabetes
Single Doses of Sitagliptin Increase Incretin Levels Over 24 Hours
TNT: Intensive Atorvastatin Treatment Reduces Cardiovascular Events in Patients With CHD and Diabetes
Plasticity of Islets: Experimental Increase in Beta-Cell Mass in Response to IR
Hypothetical Relationships Determine Categories of Glucose Tolerance
Hypothetical Outcomes of Interventions to Treat Type 2 Diabetes
Hypothetical Outcomes of Interventions to Prevent Type 2 Diabetes
Type 2 Diabetes: Pathogenesis in a Nutshell
Finnish Diabetes Prevention Study: Sustained Benefit of Lifestyle Intervention
Change in Body Weight Following 82 Weeks of Exenatide Treatment
Patients Achieving ADA A1C Goal on 18-Wk Sitagliptin Monotherapy
18-Wk Sitagliptin Monotherapy Improves Glycemic Control
18-Wk Sitagliptin Monotherapy Improves b-Cell Function
Type 2 Diabetes: Pathogenesis in a Nutshell (cont.)
Decreased beta-Cell Function in Groups With Diabetes and at High Risk
Short-term beta-Cell Adaptation: Response to Pregnancy
Declining beta-Cell Function: Best Correlation of Progression
Loss of beta-Cell Function in People Who Develop Type 2 Diabetes: Longitudinal Data
UKPDS: Progressive Deterioration in Glycemic Control Over Time
UKPDS: Progressive Deterioration in beta-Cell Function Over Time
Early Nutrient-Induced Insulin Secretion
Acute Insulin Response to Glucose
Acute Insulin Response to Arginine
Decreases in Insulin Response
Beta-Cell Mass in Normal Patients and Patients With Diabetes: Autopsy Study
Altered beta-Cell Mass and Function in Islets From Subjects With Type 2 Diabetes
Role of Islet Amyloid in beta-Cell Dysfunction
Amyloid Deposits in Pancreatic Islets in Type 2 Diabetes
24-Week Sitagliptin Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes
Sitagliptin Enhances Glycemic Control, beta-Cell Function in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Improves Glycemic Control in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
ADOPT: Cumulative Incidence of Monotherapy Failure at 5 Years
ADOPT: Adverse Events
ADOPT: Achievement of A1C Levels <7%
Vildagliptin + Pioglitazone Improves A1C in Patients Not Controlled With Thiazolidinedione Monotherapy
Vildagliptin + Pioglitazone Increases Beta-Cell Insulin Secretory Rate
Effects of Sitagliptin vs Glipizide on Body Weight in Type 2 Diabetes
Change in A1C for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Sitagliptin + Metformin Improves 24-Hour Glycemic Control
Vildagliptin: Change in Mean A1C During 24-Week Treatment
Vildagliptin: Percentage of Patients Achieving A1C <7%
Thiazolidinediones vs Insulin: Comparison of Diabetes-Related Healthcare Utilization and Costs Over 12 Months
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
Sitagliptin Improves A1C in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin on 2-Hour Post-Meal Plasma Glucose in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Monotherapy Reduces FPG in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on 2-Hour Postprandial Glucose in Patients With Type 2 Diabetes
Sitagliptin Improves A1C in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Changes in A1C Subgroups for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Effects of Sitagliptin vs Glipizide on FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Exenatide + TZD on Blood Glucose in Patients With Type 2 Diabetes
Effect of Exenatide + TZD on Body Weight in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on FPG in Patients with Type 2 Diabetes
RECORD: Study Design
RECORD: Effect of Rosiglitazone or Metformin Add-on to Sulfonylurea on A1C and FPG
RECORD: Effect of Rosiglitazone or Sulfonylurea Add-on to Metformin on A1C and FPG
Effect of Sitagliptin + Metformin on B-Cell Function at 24 Weeks
RENAAL: Design, Hypothesis, and Baseline Demographics
IDNT: REnoprotective Effects of Irbesartan in Type 2 Diabetes
Diet Does Not Affect BP in Patients With Type 2 Diabetes in the Short-Term
High-Carbohydrate Diet Elevates BP in Patients With Type 2 Diabetes
RENAAL: Impact of Losartan in Chronic Kidney Disease
RENAAL: Risk Reduction With Losartan--Design
DPP: Incidence of Type 2 Diabetes
CVD Risk Reduction From Tight Control of BP and Glucose in Type 2 Diabetes
Microalbuminuria Predicts CV Risk at Levels Below Current Definition
IRMA 2: Renoprotectie Effects of Irbesartan in Type 2 Diabetes
CALM: Renoprotection With Candesartan vs Lisinopril in Type 2 Diabetes
East-West Study: 7-Year Incidence of Fatal and Nonfatal MI in Type 2 Diabetes and CHD
IRAS: CVD Risk Factors Are Also Risk Factors for Type 2 Diabetes
Albuminuria as Independent Risk Factor for Mortality in Type 2 Diabetes
Elevated Risk of CVD Prior to Clinical Diagnosis of Type 2 Diabetes
MICRO-HOPE: ACEI Reduces Risk of Nephropathy and CHF in Patients With Type 2 Diabetes
Stroke Risk in Type 2 Diabetes: First 5 Years After Beginning Treatment
Age-Standardized Stroke Rates in Newly Treated Diabetes vs Control
Stroke Risk by Age in Type 2 Diabetes: First 5 Years After Starting Treatment
Cardiovascular Impact of Pioglitazone Therapy: A Meta-analysis
Long-term Risk of Myocardial Infarction With Rosiglitazone: A Meta-analysis
Long-term Risk of Heart Failure With Rosiglitazone: A Meta-analysis
Long-term Risk of Cardiovascular Mortality With Rosiglitazone: A Meta-analysis
Effects of Exenatide LAR on A1C in Patients With Type 2 Diabetes
Effects of Exenatide LAR on Weight in Patients With Type 2 Diabetes
Duration of TZD Therapy Prior to Onset of Heart Failure
Dose and Duration of TZD Therapy Prior to Onset of Heart Failure
Pioglitazone Reduces the Risk of Hospitalization for AMI
GLAI: Comparison of TZDs on Lipoprotein Subclass Particle Size
Proportion of Diabetic Patients With Low HDL-C Stratified by Treatment, Sex, and Cardiovascular Disease
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for GLP-1 Analogues vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
Hypoglycemia Risk Factors in Elderly Patients With Type 2 Diabetes
Suitability of DPP-4 Inhibitors for Elderly Patients With Type 2 Diabetes
Steno-2: Percentage of Patients at Treatment Goals at End of Study
Steno-2: Effect of Multifactorial Intervention on Mortality in Type 2 Diabetes
Steno-2: Effect of Multifactorial Intervention on CV Events in Type 2 Diabetes
Steno-2: Effect of Multifactorial Intervention on Various CV Events in Type 2 Diabetes
Steno-2: Effect of Multifactorial Intervention on Diabetic Complications
Steno-2: Effect of Multifactorial Intervention on Diabetic Neuropathies
Effect of Sitagliptin Added to Glimepiride and/or Metformin in Patients With Type 2 Diabetes
Glycemic Control With Addition of Sitagliptin to Glimepiride and/or Metformin
Effect of Vildagliptin Added to Glimepiride on ß-Cell Function in Patients With Type 2 Diabetes
ACCORD: Study Design
ACCORD: Results
ADVANCE: Study Design
ADVANCE: Death from Any Cause
ADVANCE: Primary Endpoints
ADVANCE Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ADVANCE Trial: Combined Major Macrovascular and Microvascular Events
ADVANCE Trial: Risk for Major Macrovascular and Microvascular Events
ACCORD Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ACCORD Trial: CV Events With Intensive Blood Glucose Control
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: A1C
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: Body Weight
Once-Weekly Exenatide LAR vs Twice-Daily Exenatide for Type 2 Diabetes: A1C Categories
Alogliptin Monotherapy: A1C
Alogliptin Added to Insulin: A1C
12-Week Saxagliptin Improves Glycemic Control in Drug-Naïve Patients
Effect of Sitagliptin vs Rosiglitazone When Added to Metformin Monotherapy
POPADAD Trial: Causes of Death in Patients With Diabetes According to
POPADAD Trial: Effect of Antioxidant Use on Events in Patients With Diabetes
POPADAD Trial: Effect of Aspirin Use on Events in Patients With Diabetes
PROactive 10 Substudy: Time to CV Death, Nonfatal MIa, Nonfatal Stroke
PROactive 10 Substudy: Time to All-Cause Mortality, Nonfatal MIa, Nonfatal Stroke, or ACS
VADT: Comparing Intensive With Standard Glucose Therapy, Primary Outcome
VADT: Comparing Intensive With Standard Glucose Therapy, Secondary Outcomes
VADT: Comparing Intensive With Standard Glucose Therapy, Change in Median A1C
VADT: Comparing Intensive With Standard Glucose Therapy, Adverse Events
Type 2 Diabetes Therapy and Cardiovascular Events: Comparing VADT With Other Trials
ACCORD-MIND: Relationship Between Glycemia Status, Diabetes Duration, and Cognitive Test Scores
ACCORD-MIND: Relationship Between Glycemia Status, CVD, Stroke, Smoking Status, and Cognitive Test Scores
High-Monounsaturated Fat Diet Vs High-Carbohydrate Diet: Effects on A1C, Glucose, Body Weight
IRAS: Risk of Type 2 Diabetes Based on Food-Pattern Score at Baseline
IRAS: Risk of Type 2 Diabetes by Food-Pattern Score and Obesity Status
Fasting Levels of Intact GIP and GLP-1 Concentrations and DPP-4 Activity in Patients With Diabetes
HEART2D: Primary Outcome Vs Days in Trial by Treatment Strategy
HEART2D Trial: A1C Values at Each Visit for 60 Months
Retinopathy Stage, Mean A1C, and Mean Systolic Blood Pressure by Ethnicity
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes
Alogliptin Study 010, Primary Endpoint: Change in A1C at 26 Weeks
Alogliptin Study 010: Secondary Measurements of A1C at Week 26
Alogliptin Study 010, Secondary Efficacy Endpoint at Week 26: Hyperglycemia
Alogliptin Study 010: Exploratory Endpoints of Alogliptin Therapy vs Placebo
Alogliptin Study 010: Safety
Survival Functions for the Secondary Macrovascular Endpoint
PROactive 10 Substudy: Time to First Event from MACE Endpoint
Vildagliptin vs Metformin: A1C
Survival Functions for the Primary Macrovascular Endpoint
Improved Glycemic Control When Adding Metformin to Insulin Therapy
Indian Diabetes Prevention Programme-2: Study Design
Indian Diabetes Prevention Programme-2: Results
Whitehall II: Design
Whitehall II: Fasting Glucose From Baseline to 13 Years
Whitehall II: 2-Hour Postload Glucose From Baseline to 13 Years
Whitehall II: HOMA Insulin Sensitivity Trajectory Before Diagnosis of Diabetes or End of Follow-Up
Whitehall II: HOMA b-Cell Function Trajectory Before Diagnosis of Diabetes or End of Follow-Up
Whitehall II: Conclusion
RECORD: Study Design
RECORD: CV Death and Hospitalization
RECORD: Time to Primary Endpoint
RECORD: Bone Fracture Rates in Upper and Distal Lower Limbs
RECORD: Conclusion
Whitehall II: 2-Hour Postload Glucose From Baseline to 13 Years
ACCORD: A1C and Mortality Risk
ACCORD: Annual Incidence of Hypoglycemia in the Intensive Versus Standard Treatment Groups
ACCORD: Hypoglycemia and Mortality
VADT: Primary Endpoint
VADT: Effect of BMI on Rates of Severe Hypoglycemia
Risk of CVD Mortality Risk rate Among Men with MetSyn and Diabetes, Alone and in Combination
Hazard Ratios of CVD Mortality Among Men With MetSyn and Diabetes, Alone and in Combination
Saxagliptin for Treatment of Type 2 Diabetes: Design
Saxagliptin for Treatment of Type 2 Diabetes: Mean Change in A1C from Baseline to Week 24
Saxagliptin for Treatment of Type 2 Diabetes: Mean Change in FPG from Baseline to Week 24
Effect of Mediterranean-Style Diet on Need for Diabetes Therapy
Risk of Cardiovascular Events During Treatment with Pioglitazone or Rosiglitazone: Design
Risk of Cardiovascular Events During Treatment with Pioglitazone or Rosiglitazone: Composite Outcome
ADVANCE Substudy: Effects of BP Lowering and Intensive Glucose Control on Retinopathy
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
Liraglutide Vs Sigagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: Design
Liraglutide Vs Sitagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: A1C
CANOE: Low-Dose Combination Therapy With Rosiglitazone Plus Metformin for Diabetes Prevention
CANOE: Development of New-Onset Diabetes With Low-Dose Combination Therapy Vs Placebo
LOADD: Nutritional Intervention for Persistent, Treated Hyperglycemia
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results Design
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results A1C Reduction
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results
BP and Type 2 Diabetes Risk in African Americans and Whites: Design
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
High-Normal A1C as a Type 2 Diabetes Predictor: Design
High-Normal A1C as a Type 2 Diabetes Predictor: Results
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Design
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Results
Effect of Liraglutide and Insulin on Cardiovascular Disease Risk Factors
Liraglutide Effect on Cardiovascular Disease: Results Among Patients Switched from Exenatide
San Luigi Gonzaga Diabetes Study: Design
San Luigi Gonzaga Diabetes Study: Results
Diabetic Retinopathy and Sight-Threatening Conditions: Prevalence and Subgroup Data
Incidence of CVD in Patients With Type 2 Diabetes and No CVD History
CVD Event Prediction in Patients With Type 2 Diabetes and No CVD History
DURATION-4: Design
DURATION-4: Mean Change in A1C from Baseline to Week 26
DURATION-4: Additional Outcomes
DURATION-4: Most Common Adverse Events
ACCORD Substudy: Impact of Frequent and Unrecognized Hypoglycemia on Mortality—Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Additional Results
STAMPEDE: Design
STAMPEDE Results: Primary Endpoint (A1C ≤6%) at 12 Months
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Design
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Results
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Additional Results
ACP: Recommendations for Oral Pharmacologic Therapy for Type 2 Diabetes
ACP: Considerations for Oral Pharmacologic Therapy in Type 2 Diabetes
ORIGIN Trial: Design
ORIGIN Trial: Baseline Characteristics (1 of 2)
ORIGIN Trial: Baseline Characteristics (2 of 2)
ORIGIN Trial: Results
DPP and DPPOS: Timeline
DPP: A Look Back
TODAY Study: Design
TODAY Study: Eligibility Criteria and Run-in Period
TODAY Study: Baseline Characteristics
TODAY Study: Primary Outcome—Loss of Glycemic Control
TINSAL-T2D Trial: Design
TINSAL-T2D Trial: Eligibility Criteria and Study Protocol
TINSAL-T2D Trial: Baseline Characteristics
TINSAL-T2D Trial: Primary Outcome—Change in A1C
TINSAL-T2D Trial: Change in Fasting Glucose Concentration
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
EASIE Trial: Design
EASIE Trial: Study and Enrollment Profile
EASIE Trial: Efficacy Population Primary Outcome at Week 24—Change in A1C from Baseline
EASIE Trial: Efficacy Population A1C <7.0% and <6.5% Week 24
EASIE Trial: Safety Population Hypoglycemia and Adverse Events
Vascular Risk Associated with Medication-Related Hypoglycemia: Design
Cumulative Incidence of CVD: Hypoglycemia Group vs Control
Cumulative Incidence of Microvascular Complications: Hypoglycemia Group vs Control
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Design
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Change in A1C from Baseline
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Adverse Events and All-Cause Mortality
ORIGIN: Design
EUREXA Trial: Change in Body Weight
EUREXA Trial: Hypoglycemia and Adverse Events
EUREXA Trial: Attainment of A1C <7.0% and ≤6.5%
EUREXA Trial: Primary Outcome—Time to Treatment Failure
EUREXA Trial: Design and Enrollment Profile
EUREXA Trial: Design
CONQUER: Design
BLOOM-DM: Design
BLOOM-DM: Primary and Secondary Endpoints
BLOOM-DM: Subject Profile
BLOOM-DM Co-Primary Endpoint: Proportion of Subjects Achieving ≥5% Reduction in Baseline Body Weight
BLOOM-DM Co-Primary Endpoint: Change in Body Weight
BLOOM-DM Co-Primary Endpoint: Proportion of Subjects Achieving ≥10% Reduction in Baseline Body Weight
BLOOM-DM: Secondary Endpoints
BLOOM-DM: Adverse Events
SEQUEL: Design Extension of CONQUER Study
Long-term Weight Loss After Roux-en-Y Gastric Bypass
Long-term Change in BMI After Roux-en-Y Gastric Bypass
JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
JUPITER Analysis: Limitations
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Glycemic Control Results
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Operative Safety, Waist Circumference
AusDiab Substudy: Design
AusDiab Substudy: Physical Health Component Summary (PCS) Results
AusDiab Substudy: Mental Health Component Summary (MCS) Results
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Design
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Additional Parameters
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Design
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Change in A1C from Baseline
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Secondary Endpoints
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: CV Safety, Glucose, Adverse Events
SOS Analysis: Design
SOS Analysis: Mean Baseline Characteristics
SOS Analysis: Rate of Diabetes Incidence
SOS Analysis: Rate of Diabetes Incidence by Subgroup
SOS Analysis: Interaction Between Risk Factors and Treatment
SOS Analysis: Sensitivity Analyses; Adverse Events
Look AHEAD: 1-Year Interim Results
Look AHEAD at 1 Year: Interventions
Look AHEAD at 1 Year: Change in Body Weight
Look AHEAD at 1 Year: Change in Fitness Levels
Look AHEAD at 1 Year: Additional Results
Look AHEAD: Design
Look AHEAD: 4-Year Data Analysis
Look AHEAD at 4 Years: Weight Reduction
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Key Facts on Prevalence, Epidemiology
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (2 of 3)
FIN-D2D: Association Between Statin Use and Diabetes Incidence Design
FIN-D2D: Statin Use at Baseline and Diabetes Incidence At 1 Year
RYGB Surgery: Long-Term Health-Related Outcomes Design
RYGB Surgery: Remission of Hypertension, Dyslipidemia Values at 6 Years
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: Design
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: 26-Week Extension Results for A1C Reduction
Liraglutide Treatment for 78 Weeks: Reductions in A1C from Baseline
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Design
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Results for Primary Endpoint
DURATION-6: Design
DURATION-6: Change in A1C at Week 26
DURATION-6: Secondary Endpoints
DURATION-6: Adverse Events
ADVANCE Post-hoc Analysis: Low HDL-C and Microvascular Event Risk
VADT Post-hoc Analysis: Statin Use and Artery Calcification
SOS Post-hoc Analysis: Effect of Bariatric Surgery on CV Events
SOS Post-hoc Analysis: Total CV Events in Obese Subjects with Type 2 Diabetes
SOS Post-hoc Analysis: MI in Obese Subjects with Type 2 Diabetes
SOS Post-hoc Analysis: Stroke in Obese Subjects with Type 2 Diabetes
Guidelines for Children and Adolescents With Type 2 Diabetes: Insulin Therapy
Guidelines for Children and Adolescents With Type 2 Diabetes: Lifestyle Changes, Metformin for All
Guidelines for Children and Adolescents With Type 2 Diabetes: A1C Testing
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (1 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (2 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Weight Loss, Diet (1 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Weight Loss, Diet (2 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Physical Activity
Comorbidities in Children and Adolescents With Type 2 Diabetes: Retinopathy
Comorbidities in Children and Adolescents With Type 2 Diabetes: Microalbuminuria
Comorbidities in Children and Adolescents With Type 2 Diabetes: Depression
Comorbidities in Children and Adolescents With Type 2 Diabetes: Obesity-Related Medical Conditions
Comorbidities in Children and Adolescents With Type 2 Diabetes: Hypertension
Comorbidities in Children and Adolescents With Type 2 Diabetes: Dyslipidemia (1 of 2)
Comorbidities in Children and Adolescents With Type 2 Diabetes: Dyslipidemia (2 of 2)
Type 2 Diabetes Remission in Look AHEAD
Look AHEAD: Partial or Complete Type 2 Diabetes Remission
Look AHEAD: Return to Clinical Diabetes Status By Year
Look AHEAD: Continuous, Sustained Type 2 Diabetes Remission
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Background
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Design
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Primary Endpoint
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Mean A1C Change
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: A1C Target at Endpoint
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Mean Body Weight Change
Can Coronary Artery Calcium Predict CVD Outcomes in Type 2 Diabetes?
CAC and CVD Mortality in Type 2 Diabetes: Diabetes Heart Study
PREDIMED: Mediterranean Diet for Primary Prevention of CVD
ACCORD: Death from Any Cause
Weight Gain from Type 2 Diabetes Treatment in ACCORD
Weight Gain in ACCORD By Type 2 Diabetes Treatment Allocation
Relationship Between Change in Weight and Change in A1C in ACCORD
Medication Use and Weight Gain in ACCORD
Inpatient Glycemic Control: Is There an Optimal Insulin Strategy?
Basal Plus Trial: Design and Randomization
Basal Plus Trial: Improvement in Mean Daily BG
Basal Plus Trial: Target Glucose Levels
Basal Plus Trial: Hypoglycemia
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Design
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Study Protocol and Meals
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Results for Glucose and Hormones
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Indices of Insulin Action
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Summary of Findings
ADA/Endocrine Society: Impact of Hypoglycemia on Glycemic Targets
ADA/Endocrine Society: Hypoglycemia & the Elderly
CANTATA-D2: Design
CANTATA-D2: Canagliflozin Noninferior to Sitagliptin for A1C Lowering at 52 Weeks
CANTATA-D2: Significantly Greater FPG Reduction with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Significantly Greater Weight Reduction with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Significant Reductions in Systolic BP with Canagliflozin Vs Sitagliptin at 52 Weeks
CANTATA-D2: Effect of Canagliflozin Vs Sitagliptin on Lipid Values at 52 Weeks
CANTATA-D2: Adverse Events at 52 Weeks
CANTATA-M: Significant A1C Reductions with Canagliflozin Vs Placebo at 26 Weeks
CANTATA-M: Greater Proportion of Subjects Achieved A1C <7.0% with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Significant FPG Reductions with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Significant Weight Reductions with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Significant Reductions in Systolic BP Seen with Canagliflozin vs Placebo at 26 Weeks
CANTATA-M: Effect of Canagliflozin Vs Placebo on Lipid Values at 26 Weeks
CANTATA-M: Adverse Events with Canagliflozin Vs Placebo at 26 Weeks
ORIGIN-GRACE: Eligibility Criteria and Trial Profile
CANTATA-M: Design
Look AHEAD: No Reduction in CV Events with Lifestyle Changes
Look AHEAD: No Reduction in Secondary CV Outcomes with Lifestyle Changes
Look AHEAD: Greater Weight Reduction with Lifestyle Changes
Look AHEAD: Lifestyle Changes Improve Glycemic Control, CV Risk Factors
Look AHEAD: Primary Outcome, Participant Characteristics
BP Rates and All-Cause Mortality in Newly Diagnosed Type 2 Diabetes: Design
BP Rates and All-Cause Mortality in Newly Diagnosed Type 2 Diabetes: Results
Efficacy of Twice-Daily Exenatide Added to Basal Insulin for A1C Reduction: Design
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo : A1C Reduction at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Target A1C Levels at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Body Weight 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Hypoglycemia at 30 Wks
Twice-Daily Exenatide Vs Placebo Added to Basal Insulin: Adverse Events
ACCORD: Factors Associated with Increased Hypoglycemia Risk in Intensive and Standard Treatment Arms
ALTITUDE: No Reduction in CV, Renal Events with Aliskiren
ALTITUDE: Increased Hyperkalemia, Renal Impairment with Aliskiren
Meta-Analysis: Severe Hypoglycemia Associated with ~2x Risk for CVD
Diabetes Surgery Study: Greater Number of Subjects Achieved Primary Endpoint with Gastric Bypass Vs Lifestyle & Medical Management
Diabetes Surgery Study: Fewer Medications, Greater Weight Change with Gastric Bypass
Diabetes Surgery Study: Design
STAMPEDE Metabolic Substudy: A1C Improvement in All Groups at 24 Months
STAMPEDE Metabolic Substudy: Greater Reduction in Truncal Fat with Gastric Bypass Vs Sleeve Gastrectomy
STAMPEDE Metabolic Substudy: Greater Increases in Insulin Sensitivity, Beta-Cell Function with Gastric Bypass
STAMPEDE Metabolic Substudy: Design
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD Secondary Endpoint
SAVOR-TIMI 53: Saxagliptin Increased Hospitalization for Heart Failure
SAVOR-TIMI 53: Significantly Better Glycemic Control with Saxagliptin
SAVOR-TIMI 53: Safety Endpoints
SAVOR-TIMI 53: Design
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Significantly Greater A1C Change from Baseline with Alogliptin Vs Placebo
EXAMINE: Adverse Events
EXAMINE: Design
ADA Nutrition Guidelines: Nutrition Therapy
ADA Nutrition Guidelines: Energy Balance
ADA Nutrition Guidelines: Protein
ADA Nutrition Guidelines: Fats
ADA Nutrition Guidelines: Priorities for Nutrition Management for Type 1 Diabetes and Insulin-Requiring Type 2 Diabetes
LABS-2: 3-Yr Remission & Incidence of Cardiometabolic Outcomes After Bariatric Surgery
Liraglutide 12-Week Treatment: Effect on Glycemic Control
LEAD-3: Liraglutide vs Glimepiride: A1C Level
LEAD-3: Liraglutide vs Glimepiride in Drug-Naïve Patients: A1C
LEAD-3: Liraglutide vs Glimepiride in Previously on Oral Agents: A1
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, Change in A1C at 26 Weeks
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in Patients With Type 2 Diabetes
Liraglutide Improves ß-Cell Function and Insulin Secretion During Hyperglycemia in Patients With Type 2 Diabetes
Liraglutide Reduces A1C Irrespective of Baseline A1C
Liraglutide Enhances Glucose-Dependent Insulin Secretion
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Body Weight in
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Fasting Plasma
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on A1
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on Body
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on Fasting
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
AHA/ACC/TOS Obesity Guidelines: Weight Loss Outcomes in Overweight or Obese Adults
AHA/ACC/TOS Obesity Guidelines: Bariatric Surgery Outcomes
AleCardio: Time to First Occurrence of Any Part of the Composite of CV Mortality, Nonfatal MI, or Nonfatal Stroke With Aleglitazar Vs Placebo
AleCardio: Aleglitazar Safety Vs Placebo
AleCardio: Design
STAMPEDE: A1C Less Than or Equal to 6.0 Percent at 3 Yrs With Bariatric Surgery Vs Medical Therapy
US Trends in Type 2 Diabetes Treatment, 1997-2012: Type of Treatment Used, Visit with 2+ Compounds in 2012
US Trends in Type 2 Diabetes Treatment, 1997-2012: Type of Treatment Used, Visit with 1 Compound in 2012
US Trends in Type 2 Diabetes Treatment, 1997-2012: Number of Treatments
US Trends in Type 2 Diabetes Treatment, 1997-2012: Insulin Use
US Trends in Type 2 Diabetes Treatment, 1997-2012: Medication Classes
SEQUEL Subanalysis: Percent Weight Loss from Baseline at Wk 108 Primary Endpoint
SEQUEL Subanalysis: Annualized Incidence of Type 2 Diabetes at Wk 108
SEQUEL Subanalysis: Reduction of Type 2 Diabetes Incidence Related to Greater Weight Loss
SEQUEL Subanalysis: Design
Type 2 Diabetes Treatment Intensification Micro- Macrovascular | NDEI
Type 2 Diabetes Treatment Intensification Acute MI | NDEI
Type 2 Diabetes Treatment Intensification Albuminuria | NDEI
Type 2 Diabetes Treatment Intensification eGFR Kidney | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
ACC/AHA Lifestyle Management Mediterranean Diet Lipids BP | NDEI
LEAD 6: Study Design
LEAD 6: Change in A1C at 26 Weeks
LEAD 6: Percent at A1C Targets at 26 Weeks
LEAD 6: Change in FPG at 26 Weeks
LEAD 6: Change in Weight at 26 Weeks
IDF 2012 Type 2 Diabetes Guidelines Screening Diagnosis | NDEI
IDF 2012 Type 2 Diabetes Guidelines Care Delivery | NDEI
IDF 2012 Type 2 Diabetes Guidelines Psychological Education | NDEI
IDF 2012 Type 2 Diabetes Lifestyle Management Guidelines | NDEI
IDF 2012 Type 2 Diabetes Guidelines Dietary Guidelines | NDEI
IDF 2012 Type 2 Diabetes Guidelines Exercise Physical Activity | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Glycemic Control | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Monitoring | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Treatment Management | NDEI
IDF 2012 Type 2 Diabetes Guidelines Insulin Therapy | NDEI
IDF 2012 Type 2 Diabetes Guidelines Blood Pressure Targets | NDEI
IDF 2012 Type 2 Diabetes Guidelines Blood Pressure Treatment | NDEI
IDF Type 2 Diabetes Guidelines Cardiovascular Risk | NDEI
IDF Type 2 Diabetes Guidelines CVD Risk Reduction Treatment | NDEI
IDF Type 2 Diabetes Guidelines Retinopathy Eye Screening | NDEI
IDF Type 2 Diabetes Guidelines Kidney Disease | NDEI
IDF Type 2 Diabetes Guidelines Foot Care | NDEI
IDF Type 2 Diabetes Guidelines Foot Care Amputation Ulceration | NDEI
IDF Type 2 Diabetes Guidelines Neuropathy | NDEI
IDF Guidelines Type 2 Diabetes Diagnosis Older Adults Elderly | NDEI
IDF Type 2 Diabetes Treatment Guidelines Older Adults Elderly | NDEI
IDF Type 2 Diabetes Guidelines In-Patient | NDEI
IDF Type 2 Diabetes Guidelines In-Patient Critically Ill | NDEI
Emplagliflozin SGLT 2 A1C EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Weight Loss EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Insulin EMPA-REG MDI Study | NDEI
Empagliflozin SGLT2 Adverse Events EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 EMPA-REG MDI Study | NDEI
Canola Oil Glycemia A1C Type 2 Diabetes | NDEI
Canola Oil Glycemic Control CVD Type 2 Diabetes | NDEI
Canola Oil Study Glycemic Control A1C Type 2 Diabetes | NDEI
Diabetes Cognitive Dysfunction | NDEI
Type 2 Diabetes Alzheimer Disease | NDEI
Type 2 Diabetes Treatments Used for Alzheimer Disease? | NDEI
Canola Oil Diet Study Glycemia A1C Type 2 Diabetes | NDEI
Bariatric Surgery Type 2 Diabetes Remission SOS Study | NDEI
Bariatric Surgery Type 2 Diabetes Complications SOS Study | NDEI
Bariatric Surgery Type 2 Diabetes Weight Loss | NDEI
SOS Study Bariatric Surgery Type 2 Diabetes Design | NDEI
SAVOR TIMI Saxagliptin Pancreatitis | NDEI
SAVOR TIMI 53 Pancreatitis Risk Factors Saxagliptin DPP-4 | NDEI
No Pancreatic Cancer Signal Saxagliptin DPP-4 SAVOR TIMI | NDEI
SAVOR TIMI 53 Pancreatitis Cancer Saxagliptin DPP-4 | NDEI
Diabetes Pregnancy Guidelines Preconception Endocrine Society | NDEI
Diabetes Pregnancy Guidelines Postpartum Care GDM | NDEI
Diabetes Pregnancy Guidelines Postpartum Lactation GDM | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
Statin Adherence Associated With Increased Type 2 Diabetes Risk | NDEI
Statin Adherence & Type 2 Diabetes Risk | NDEI
Statin Adherence & Risk for New-Onset Type 2 Diabetes | NDEI
SGLT2 Inhibitors Type 2 Diabetes Treatment Slides | NDEI
Sulfonylurea Treatment All-Cause CV Mortality Type 2 Diabetes Treatment | NDEI
Higher CV Risk With Metformin + Sulfonylurea Vs DPP-4 Inhibitor | NDEI
SGLT Glucose Homeostasis Diabetes Education Slides | NDEI
HARMONY 3 Albiglutide A1C Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide FPG Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Weight Loss Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide Type 2 Diabetes Metformin | NDEI
Metformin Sulfonylureas Cancer Risk Type 2 Diabetes | NDEI
Sulfonylureas Metformin Cancer Risk Type 2 Diabetes | NDEI
DPP-4 Inhibitors Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists A1C Type 2 Diabetes | NDEI
Basal Insulin Glycemic Control A1C Type 2 Diabetes | NDEI
HARMONY 3 DPP-4 Inhibitors Safety Pancreatitis | NDEI
Cancer Incidence Metformin Sulfonylureas Type 2 Diabetes | NDEI
Edinburgh Type 2 Diabetes Study Severe Hypoglycemia Slide PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Macrovascular Slides PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Linked to Inflammation Slides PPT | NDEI
Edinburgh Type 2 Diabetes Inflammation Doesn't Influence Hypoglycemia Slides PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Linked to Macrovascular Death Slides PPT | NDEI
ADVANCE-ON Type 2 Diabetes Study Baseline Characteristics Slide | NDEI
ADVANCE-ON Type 2 Diabetes Primary Outcomes BP Lowering Slide | NDEI
ADVANCE-ON Type 2 Diabetes Secondary Outcomes BP Lowering Slide | NDEI
ADVANCE-ON Type 2 Diabetes Primary Outcomes Intensive Glucose Slide | NDEI
ADVANCE-ON Type 2 Diabetes Intensive Control Macrovascular Slide | NDEI
Statin Use and the Risk of Microvascular Disease | NDEI
Look AHEAD Impact of Intensive Lifestyle Health Costs Diabetes Slide | NDEI
Look AHEAD Intensive Lifestyle Reduces Healthcare Use Diabetes Slide | NDEI
Look AHEAD Intensive Lifestyle Reduces Health Costs Diabetes Slide | NDEI
Look AHEAD Intensive Lifestyle Reduces 10-Yr Diabetes Health Costs | NDEI
Look AHEAD Diabetes Costs Differ By CVD History Slide | NDEI
Look AHEAD Healthcare Utilization & Cost Analysis Diabetes Slide | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission PPT Slide | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission Linked With Diabetes Duration | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission A1C Slide | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission Diabetes Medication | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission Summary | NDEI
ADVANCE-ON Type 2 Diabetes Intensive Control Design | NDEI
Prevalence & Incidence of Diabetes in the United States | NDEI Slides
Reports of Acute Pancreatitis Type 2 Diabetes Drugs | NDEI
Risk of Acute Pancreatitis Rare in Incretin-Treated Type 2 Diabetes | NDEI
SGLT2 Dapagliflozin + Insulin Type 1 Diabetes Treatment Slide | NDEI
Adverse Events Dapagliflozin As Insulin Adjunct in Type 1 Diabetes | NDEI
Dapagliflozin Pharmacokinetics in Type 1 Diabetes SGLT 2 | NDEI
Average Daily Glucose Changes & Insulin Use Dapagliflozin Type 1 Diabetes | NDEI
Dapagliflozin Type 1 Diabetes SGLT2 Data Review | NDEI
Does Early Weight Loss With Lorcaserin Predict Outcomes Obesity | NDEI
5% Weight Loss With Lorcaserin Predicts 1-Year Outcomes Obesity | NDEI
5% Weight Loss at 1 Year With Lorcaserin Vs Placebo Obesity | NDEI
10% Weight Loss at 1 Year With Lorcaserin Vs Placebo Obesity | NDEI
Early Weight Loss With Lorcaserin Predicts 1-Yr Response Obesity | NDEI
Lorcaserin Phentermine Overweight Obesity Adverse Events | NDEI
Lorcaserin + Phentermine Weight Loss Overweight Obese | NDEI
Lorcaserin + Phentermine Overweight Obese Weight Loss | NDEI
SCALE Obesity & Prediabetes Study Liraglutide Overweight Obesity | NDEI
SCALE-Diabetes Liraglutide Weight Loss QoL Obesity/Overweight | NDEI
BLOOM-DM Lorcaserin Glycemic Effect Type 2 Diabetes | NDEI
Effect of Bariatric Surgery on Type 2 Diabetes Medication Use | NDEI
Safety Bariatric Surgery for BMI <35 at 1 Year
US Adults Who May Be Candidates for Obesity Therapy | NDEI
ACCORD-MIND Hypoglycemia Brain Structure Type 2 Diabetes | NDEI
ACCORD-MIND Hypoglycemia Age, Intensive Therapy, Diabetes Duration | NDEI
ACCORD-MIND Hypoglycemia Doesn't Alter Brain Function Type 2 Diabetes | NDEI
ACCORD-MIND Summary Hypoglycemia Cognitive Function Type 2 Diabetes | NDEI
Phentermine + Topiramate for Weight Loss in Type 2 Diabetes | NDEI PPT
Greater Weight Loss With Phentermine + Topiramate Obesity Type 2 Diabetes | NDEI
Phentermine + Topiramate A1C Targets Obese Subjects With Type 2 Diabetes | NDEI
Phentermine + Topiramate Decreases Need for Antidiabetic Treatments CONQUER | NDEI
Phentermine + Topiramate Safety Obesity Type 2 Diabetes | NDEI PPT
Phentermine Plus Topiramate Weight Loss Obesity Type 2 Diabetes | NDEI
EMPA-REG Blood Pressure Lowering With Empagliflozin Type 2 Diabetes Hypertension | NDEI
EMPA-REG Blood Pressure Reductions With Empagliflozin SGLT2 | NDEI PPT
EMPA-REG A1C & Weight Loss Empagliflozin SGLT2 Type 2 Diabetes | NDEI
EMPA-REG Safety of Empagliflozin in Type 2 Diabetes & Hypertension SGLT2 | NDEI
EMPA-REG BP: A1C, BP, & Weight Reduction With Empagliflozin in Type 2 Diabetes & Hypertension Clinical Significance for HCPs
Type 1 Diabetes Incidence & Prevalence Slide PPT | NDEI
Type 1 Diabetes Classification & Diagnosis
ADA Type 1 Diabetes Guidelines Diagnosis Clues Slide | NDEI
ADA Type 1 Diabetes Guidelines Diagnostic Criteria | NDEI
Transitional Care ADA Type 1 Diabetes Guidelines | NDEI PPT
Concomitant Autoimmunity
ADA Type 1 Diabetes Guidelines Children and Adolescent Treatment | NDEI
Type 1 Diabetes Diagnosis Follow-Up ADA Guidelines | NDEI PPT
ADA Type 1 Diabetes Guidelines DSME | NDEI Diabetes Slides
ADA Type 1 Diabetes Guidelines Nutrition Therapy | NDEI Slides
ADA Type 1 Diabetes Guidelines Physical Activity | NDEI Diabetes Slides
A1C Targets for Nonpregnant Individuals
Glycemic Goals for Adults With Type 1 Diabetes
Glucose Monitoring SMBG CGM ADA Type 1 Diabetes Guidelines | NDEI
A1C Testing ADA Type 1 Diabetes Guidelines | NDEI PPT
Insulin Therapy ADA Type 1 Diabetes Guidelines | NDEI Slides
Beta-Cell Replacement ADA Type 1 Diabetes Guidelines | NDEI
Noninsulin Therapies ADA Type 1 Diabetes Guidelines | NDEI Slides
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
Diabetic Ketoacidosis Management ADA Type 1 Diabetes Guidelines | NDEI
CVD Treatment Statin ADA Type 1 Diabetes Guidelines | NDEI
A1C Targets Pregnancy ADA Type 1 Diabetes Guidelines | NDEI Slides
Pregnancy Recommendations ADA Type 1 Diabetes Guidelines | NDEI
Inpatient Outpatient Management ADA Type 1 Diabetes Guidelines | NDEI
Child Care Recommendations ADA Type 1 Diabetes Guidelines | NDEI
Psychosocial Issues ADA Type 1 Diabetes Guidelines | NDEI PPT
Inpatient Glycemia Targets ADA Type 1 Diabetes Guidelines | NDEI PPT
ADA EASD Hyperglycemia Management in Type 2 Diabetes PPT | NDEI
ADA EASD Type 2 Diabetes Treatment Hyperglycemia PPT | NDEI
Hyperglycemia Management Type 2 Diabetes ADA EASD PPT | NDEI
ADA EASD Pharmacologic Treatment Diabetes Hyperglycemia | NDEI
Type 2 Diabetes Treatment Options Hyperglycemia ADA EASD | NDEI
ADA EASD Treatment Algorithm Type 2 Diabetes | NDEI
ADA EASD Position Statement Insulin Use in Type 2 Diabetes | NDEI
DURATION-3 & LEAD-5 Post-Hoc Analysis Insulin Type 2 Diabetes PPT | NDEI
Combination GLP-1 RA & Basal Insulin Treatment Type 2 Diabetes | NDEI
Hypoglycemia & Weight After Treatment With GLP-1 RA + Basal Insulin | NDEI
Does Bariatric Surgery Influence Type 2 Diabetes Development PPT | NDEI
Incidence of Type 2 Diabetes After Bariatric Surgery Obesity PPT | NDEI
Treatment Strategies for Long-Term Weight Loss ENDO Obesity Guidelines | NDEI
Endocrine Society Obesity Guidelines Treating Type 2 Diabetes PPT | NDEI
Incretins Therapies & Heart Failure Risk in Type 2 Diabetes PPT | NDEI
No Increased Acute Pancreatitis Risk With Incretins Type 2 Diabetes | NDEI
Reduction in SBP Lowers Cardiovascular Risk in Type 2 Diabetes PPT | NDEI
SBP Reduction Microvascular Outcomes in Type 2 Diabetes PPT | NDEI
BP-Lowering Treatment & Macrovascular Outcomes Type 2 Diabetes | NDEI
SCALE Obesity & Prediabetes Trial Liraglutide GLP-1 Design PPT | NDEI
SCALE Trial FPG Liraglutide Vs Placebo in Obese Subjects PPT | NDEI
SCALE Obesity & Prediabetes Liraglutide Blood Pressure PPT | NDEI
SCALE Obesity & Prediabetes Trial Liraglutide Hypoglycemia PPT | NDEI
Canagliflozin & Sitagliptin A1C Type 2 Diabetes ENDO2015 PPT | NDEI
Empagliflozin Vs Linagliptin First-Line Type 2 Diabetes Treatment ENDO2015 | NDEI
Empagliflozin Vs Linagliptin 2nd-Line Therapy Type 2 Diabetes Obesity ENDO2015 | NDEI
Weight Loss With Liraglutide 3 mg Obese With Prediabetes SCALE ENDO2015 | NDEI
Safety & Efficacy of Lorcaserin + Phentermine Among Overweight or Obese Subjects
AACE 2015 Guidelines Type 2 Diabetes Diagnosis Screening PPT | NDEI
AACE 2015 Guidelines Criteria for Diagnosing Type 2 Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Lifestyle Changes Diet Exercise PPT | NDEI
AACE 2015 Diabetes Guidelines Nephropathy Management Microvascular | NDEI
AACE 2015 Diabetes Guidelines Retinopathy Management PPT | NDEI
AACE 2015 Diabetes Guidelines Neuropathy Management PPT | NDEI
AACE 2015 Diabetes Guidelines Glucose Monitoring CGM SMBG PPT | NDEI
AACE 2015 Diabetes Guidelins Glycemic Targets Pregnancy GDM PPT | NDEI
ADA EASD Position Statement Individualized Glycemic Targets PPT | NDEI
ELIXA No Cardiovascular Risks Lixisenatide GLP-1 CV Safety | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI
TECOS Sitagliptin Cardiovascular Safety High-Risk Type 2 Diabetes DPP-4 | NDEI
TECOS Cardiovascular Outcomes Sitagliptin DPP-4 | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
TECOS Sitagliptin DPP-4 Inhibitor Pancreatitis Hypoglycemia | NDEI
TECOS Sitagliptin A1C Efficacy DPP-4 Inhibitor CV Safety | NDEI
Efficacy and Safety of Ranalozine on Glycemia in Type 2 Diabetes
Ranalozine Superior to Placebo for A1C Reduction in Type 2 Diabetes
Efficacy and Safety of Saxagliptin in Older Adults in SAVOR-TIMI 53
No Increased Ischemic Events With Saxagliptin Vs Placebo in Older Adults in SAVOR-TIMI 53
Mean A1C Reduction With Saxagliptin in Older Adults in SAVOR-TIMI 53
AHA ADA Guidelines Diabetes CVD PPT | NDEI
AHA ADA Diabetes Diagnosis Criteria Guidelines PPT | NDEI
Lifestyle Management for CVD Prevention in Diabetes AHA ADA | NDEI
Lifestyle for Weight Loss in Diabetes AHA ADA Guidelines | NDEI
Pharmacologic Therapy for Weight Loss Type 2 Diabetes AHA ADA | NDEI
Diabetes Medications & Weight AHA ADA CVD Prevention Guidelines | NDEI
Bariatric Metabolic Surgery for Weight Loss Type 2 Diabetes AHA ADA | NDEI
Bariatric Surgery for Weight Loss in Type 2 Diabetes for CVD Prevention | NDEI
Individualized Diabetes Therapy for CVD Prevention in Type 2 Diabetes AHA ADA | NDEI
A1C Targets AHA ADA Guidelines Type 2 Diabetes CVD Prevention | NDEI
Type 2 Diabetes & CVD Risk AHA ADA Guidelines PPT | NDEI
Blood Pressure Targets Type 2 Diabetes AHA ADA Guidelines | NDEI
Cholesterol Targets LDL Type 2 Diabetes AHA ADA Guidelines | NDEI
Aspirin Therapy Type 2 Diabetes CVD Prevention PPT | NDEI
Kidney Disease in Type 2 Diabetes for CVD Prevention PPT | NDEI
Hypoglycemia & CVD Risk Type 2 Diabetes AHA ACC Guidelines PPT | NDEI
IMPROVE-IT Ezetimibe Simvastatin Reduces CV Events Type 2 Diabetes | NDEI
Ezetimibe/Simvastatin Reduces MI & Stroke Type 2 Diabetes IMPROVE-IT | NDEI
Combo Ezetimibe/Simvastatin LDL-C Type 2 Diabetes IMPROVE-IT | NDEI
Sitagliptin Not Associated With Heart Failure in TECOS Type 2 Diabetes | NDEI
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD
EMPA-REG OUTCOME Empagliflozin CV Death Reduced Type 2 Diabetes | NDEI
Empagliflozin Reduces Death Type 2 Diabetes EMPA-REG OUTCOME EASD | NDEI
EMPA-REG OUTCOME Empagliflozin Heart Failure Type 2 Diabetes EASD | NDEI
EMPA-REG OUTCOME Empagliflozin A1C High-Risk Type 2 Diabetes | NDEI
Empagliflozin Safety Adverse Events Type 2 Diabetes EMPA-REG OUTCOME | NDEI
EMPA-REG OUTCOME Design Empagliflozin SGLT2 Type 2 Diabetes | NDEI
ACCORD BP Post-hoc Analysis: Design
Type 2 Diabetes Screening US Preventive Type 2 Diabetes Guidelines | NDEI
Type 2 Diabetes Risk Factors US Preventive Services Guidelines | NDEI
Blood Glucose Values Indicating Prediabetes or Type 2 Diabetes
Type 2 Diabetes Risk Factors Screening US Preventive Guidelines | NDEI
Type 2 Diabetes Diagnostic Criteria US Preventive Guidelines | NDEI
Antibiotics & Risk of Type 2 Diabetes PPT | NDEI
Insulin Glargine A1C Reduction Type 2 Diabetes PPT | NDEI
Subjects With Type 2 Diabetes at Higher Dementia Risk: Meta-Analysis
AWARD-2: Once-Weekly Dulaglutide Vs Insulin Glargine Type 2 Diabetes | NDEI
Lower A1C With Dulaglutide Vs Insulin Glargine AWARD-2 Results | NDEI
Saxagliptin Not Associated With Fractures in SAVOR-TIMI 53 Analysis | NDEI
Safety of Dulaglutide & Insulin Glargine Pancreatitis AWARD-2 | NDEI
Cognitive Dysrunction in Type 2 Diabetes ADA Guidelines | NDEI PPT
Criteria for Type 2 Diabetes Diagnosis ADA Guidelines 2016 | NDEI PPT
Screening for Type 2 Diabetes & Prediabetes in Asymptomatic Individuals
Prediabetes Increases Type 2 Diabetes Risk ADA Guidelines | NDEI PPT
Type 1 Diabetes Screening ADA Guidelines 2016 | NDEI PPT
Type 2 Diabetes and Prediabetes Screening for Children ADA Guidelines | NDEI
Diagnosing Gestational Diabetes Mellitus GDM ADA Guidelines | NDEI PPT
Diabetes Comorbities ADA Guidelines | NDEI PPT
Fatty Liver Disease Is A Diabetes Comorbidity ADA Guidelines | NDEI
Sleep Apnea Is A Diabetes Comorbidity ADA Guidelines | NDEI
Cancer Is A Diabetes Comorbidity ADA Guidelines | NDEI PPT
Fractures Are A Diabetes Comorbidity ADA Guidelines | NDEI
Low Testosterone Is A Comorbidity of Diabetes ADA Guidelines | NDEI
Hearing Impairment Is A Diabetes Comorbidity ADA Guidelines | NDEI
Cognitive Impairment & Diabetes ADA Guidelines Slide | NDEI
Physical Activity Recommendations 2016 ADA Diabetes Guidelines | NDEI
Psychosocial Assessment and Care in Type 2 Diabetes ADA Guidelines | NDEI
Vaccines in Patients With Type 2 Diabetes ADA Guidelines | NDEI PPT
Type 2 Diabetes Prevention ADA Guidelines 2016 | NDEI PPT
Continuous Glucose Monitoring (CGM) Insulin Type 2 Diabetes ADA Guidelines | NDEI
Type 1 Diabetes Treatment Options ADA Guidelines 2016 | NDEI PPT
Pharmacologic Therapy for Type 2 Diabetes ADA Guidelines | NDEI PPT
Type 2 Diabetes Treatment Algorithm ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
ADA Obesity Management Guidelines in Patients With Type 2 Diabetes | NDEI
Treatment for Overweight & Obesity in Type 2 Diabetes ADA Guidelines | NDEI
Obesity Treatment Options Type 2 Diabetes ADA Guidelines | NDEI PPT
Bariatric Surgery in Type 2 Diabetes ADA Guidelines | NDEI PPT
Hypertension Treatment Options in Diabetes ADA Guidelines | NDEI PPT
Lifestyle Changes for Hypertension in Diabetes ADA Guidelines | NDEI PPT
Lipid Management Recommendations ADA Diabetes Guidelines | NDEI
Statin Therapy in Type 2 Diabetes ADA Guidelines 2016 | NDEI PPT
Combination Statin Therapy in Type 2 Diabetes ADA Guidelines | NDEI PPT
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
Antiplatelet Therapy Recommendations ADA Guidelines | NDEI PPT
CHD Screening & Treatment ADA Diabetes Guidelines | NDEI PPT
Retinopathy Screening Recommendations ADA Guidelines | NDEI PPT
ADA Guidelines for Retinopathy Treatment 2016 | NDEI PPT
Neuropathy Management ADA Diabetes Guidelines 2016 | NDEI PPT
Foot Care in Patients With Diabetes ADA Guidelines | NDEI PPT
Glycemic Targets for Children With Type 1 Diabetes ADA Guidelines | NDEI
Screening for Autoimmunities in Children With Type 1 Diabetes ADA | NDEI
2016 ADA Guidelines for Treating Hypertension in Children With Type 1 Diabetes | NDEI